Teva Pharmaceutical Industries
received tentative approval for its generic version of
migraine drug Imitrex.
Teva's version of the drug, also known as sumatriptan succinate, is expected to receive final approval in February 2009, after Glaxo's patent on the drug expires. In the 12 months ended this past September, the branded medication brought in $910 million in sales, Teva says.
U.S. regulators granted tentative clearance for 25, 50 and 100 milligram dosage levels of the drug. Teva's generic is considered a bioequivalent to the branded version of the acute migraine treatment, meaning it's not significantly different in formulation or effectiveness from the original Glaxo drug.
Israel-based Teva is the world's biggest maker of generic medicines.